grant
Novel Biomarkers Predicting Blood Clots in Ovarian Cancer
Organization UNIVERSITY OF TX MD ANDERSON CAN CTRLocation HOUSTON, UNITED STATESPosted 19 Sept 2023Deadline 31 Jul 2028
NIHUS FederalResearch GrantFY2025Active OxygenAdjuvant ChemotherapyAdjuvant Drug TherapyAntibiotic AgentsAntibiotic DrugsAntibioticsAnticoagulationAntioxidantsAntithrombotic AgentsAntithrombotic DrugsBiochemicalBiological MarkersBleedingBloodBlood ClottingBlood NeutrophilBlood PlasmaBlood PlateletsBlood Polymorphonuclear NeutrophilBlood Reticuloendothelial SystemBlood SampleBlood coagulationBlood specimenBrain CancerCancer InductionCancer PatientCancersCell BodyCellsClinicalClosure by LigationDNA mutationDataEarly InterventionExpression SignatureFibrinolytic AgentsFibrinolytic DrugsGene ExpressionGene Expression ProfileGene variantGeneral PopulationGeneral PublicGenerationsGenesGenetic ChangeGenetic MarkersGenetic defectGenetic mutationGenetic predisposing factorGoalsHaplogroupHemorrhageHemostatic AgentsHemostaticsHypercoagulabilityInduction TherapyInjectionsInstitutionLaboratoriesLigationMDACCMalignant CellMalignant NeoplasmsMalignant Ovarian NeoplasmMalignant Ovarian TumorMalignant TumorMalignant Tumor of the BrainMalignant Tumor of the OvaryMalignant neoplasm of brainMalignant neoplasm of ovaryMarrow NeutrophilMarrow plateletMethionineMiceMice MammalsMiscellaneous AntibioticMitochondriaMitochondrial DNAMitochondrial ProteinsModelingMoonMorbidityMorbidity - disease rateMurineMusMutationNEOADJNeoadjuvantNeoadjuvant TherapyNeoadjuvant TreatmentNeutrophilic GranulocyteNeutrophilic LeukocyteNuclearOvarian TumorOvary CancerOvary NeoplasmsOvary TumorOxygen RadicalsPatientsPeptidesPhlebothrombosisPlasmaPlasma SerumPlateletsPolymorphonuclear CellPolymorphonuclear LeukocytesPolymorphonuclear NeutrophilsPro-OxidantsReactive Oxygen SpeciesReagentResearch SpecimenReticuloendothelial System, Serum, PlasmaRiskRisk FactorsRoleSamplingSomatic MutationSpecimenThrombocytesThrombolytic AgentsThrombolytic DrugsThrombophiliaThrombosisThrombusTumor-DerivedUniversity of Texas M D Anderson Cancer CenterUniversity of Texas MD Anderson Cancer CenterVenousVenous Thrombosisallelic variantantithrombotic medicationantithromboticsbio-markersbiologic markerbiomarkerbiomarker identificationblood losscancer cellcancer cell genomecancer diagnosiscancer genomecarcinogenesischemotherapyclinical databasecohortextracellularextracellular vesiclesgene biomarkergene expression biomarkergene expression patterngene expression signaturegene markergene signature biomarkergenetic biomarkergenetic make-upgenetic makeupgenetic risk factorgenetic variantgenome mutationgenomic varianthigh riskidentification of biomarkersidentification of new biomarkersimprovedinduction therapiesinherited factorinhibitormalignancymarker identificationmicrovesiclesmitochondrialmortalitymouse modelmtDNAmurine modelneoplasm/cancerneutrophilnew markernovelnovel biomarkernovel markerovarian cancerovarian neoplasmpodoplaninpredictive biological markerpredictive biomarkerspredictive markerpredictive molecular biomarkerpreventpreventingprogramsprophylacticsmall moleculesocial rolesomatic variantthromboticthrombotic diseasethrombotic disordertranscriptional profiletranscriptional signaturetumortumor DNAtumor cell DNAtumor genometumor-specific DNAvenous thromboembolismvesicle releasevesicular release
Description preview
Project Summary/Abstract
Venous thromboembolism (VTE) develops in about one-fourth of patients with ovarian cancer and is associated
with significant morbidity and mortality. Chemotherapy increases VTE risk, but administration of prophylactic
anticoagulation to all patients on chemotherapy is associated with a substantial risk of bleeding.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click